Eli Lilly and Company (LLY) shares experienced a significant drop of over 4% in premarket trading on Friday, October 17, 2025. The decline followed comments made by President Donald Trump suggesting potential price reductions for popular GLP-1 weight-loss medications. During a press conference, Trump stated that the prices for these drugs, referring to Ozempic as "the fat loss drug," would be "much lower" than their current list prices. This has sparked investor concern regarding the future revenue and profitability of Eli Lilly's blockbuster drugs, Mounjaro and Zepbound, which are in the same class of medications. While some analysts believe the market reaction is "overdone," citing that many insured patients already pay a much lower co-pay, the comments have introduced a notable headline risk for the company. JPMorgan analysts noted that the potential price points mentioned by Trump are in line with their expectations for negotiated prices and do not pose a downside to their financial models for the company.